ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

Inclusion Criteria:

• Primary hypercholesterolaemia:
• Statin naïve subjects (LDL-C level > 3.5 mmol/L) or subjects on an ineffective "start dose" of a lipid-lowering therapy (LDL-C level > 3.1 mmol/L).
• CV risk > 20%,
• history of CHD or other established atherosclerotic disease

Exclusion Criteria:

• History of severe adverse events with another HMG-CoA reductase inhibitor
• Secondary hypercholesterolaemia;
• Unstable cardiovascular disease;
• Uncontrolled diabetes, active liver disease;
• Severe hepatic or renal impairment;
• Treatment with cyclosporin.